Drug durvalumab reduces need for bladder removal, trial finds
A trial led by the Institute of Cancer Research, London, found that the immunotherapy drug durvalumab, when added to chemotherapy and radiotherapy, can spare bladder cancer patients the need for surgery to remove the bladder. Bladder cancer is the ninth most common cancer worldwide, and advanced forms often require removal of the entire bladder. The phase-two trial, funded by AstraZeneca and the University of Birmingham, tested 54 patients, and cancer did not return in 46 of them (85%). In earlier trials without immunotherapy, the combination of chemotherapy and radiotherapy prevented recurrence in 60% of patients. Results were presented at the American Society of Clinical Oncology’s annual meeting in Chicago. Researchers said the approach could be practice-changing by improving outcomes while preserving quality of life. Cancer Research UK’s chief executive called the results potentially life-changing but noted that larger-scale research is needed.
What’s reported
Key figures
Sources: The Guardian
